Please assess the completion status of the following clinical trial:

Trial Title: Developing Genetic Education for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current Smoker~* Smoking ten or more cigarettes per day~* 19 years or older~* Intention of quitting smoking in the next month~* Agree to use two forms of acceptable birth control while using the nicotine replacement patch~Exclusion Criteria:~* Not currently seeking treatment for a mental disorder with psychotic symptoms~* Not currently pregnant nor nursing~* Not been recently diagnosed or currently affected with cancer or any other life-threatening illness~* No recent heart attack~* No history of high blood pressure or not currently receiving treatment to manage high blood pressure~* No history of an irregular heartbeat~* Not currently taking medications to help quit smoking (i.e. Chantix, Zyban or Wellbutrin, NRT)~* No history of adverse effects from using nicotine replacement patches~* Not currently experiencing serious pain or discomfort due to heart disease

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Genetic Education Session (GES) (Type: EXPERIMENTAL): The objectives are to: discuss the impact of the human genome project; define basic genetic concepts and terminology; distinguish between single-gene and multifactorial genetic diseases/conditions; describe genetic counseling/testing; identify uses of pharmacogenetics; discuss psychological and legal/ethical implications of genetic discoveries; smoking as a multifactorial behavior; findings of epidemiological studies about smoking heritability; research about candidate genotypes DRD2 and CYP2A6; and potential use of genotyping to tailor smoking cessation treatment. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
- Nutrition Education Session (NES) (Type: ACTIVE_COMPARATOR): The objective is to provide a control group that will received comparable attention as the experimental group by providing USDA approved nutritional information (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).